Nicotinamide ribonucleoside ( DrugBank: Nicotinamide )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04870866 (ClinicalTrials.gov) | June 5, 2019 | 23/4/2021 | NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia | NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia | Ataxia Telangiectasia | Drug: Nicotinamide ribonucleoside | University Hospital, Akershus | The Bergesen Foundation;South-Eastern Norway Regional Health Authority;Sykehuset Innlandet HF;Oslo University Hospital;St. Olavs Hospital;Haukeland University Hospital;University Hospital of North Norway;University of Bergen | Active, not recruiting | 3 Years | N/A | All | 13 | Phase 2 | Norway |